CClinicalTrials.gg
CompletedNCT05207982Updated Jan 14, 2025Results posted

Weight Management Program for Patients With First Episode Psychosis

A Phase 1 interventional study of Family Based weight management program in Diet, Healthy and Psychotic Disorders, sponsored by State University of New York at Buffalo. Completed at 1 site in United States. Open to participants aged 14 Years to 26 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by State University of New York at Buffalo · Phase 1, Interventional, and Supportive care

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
14 Years to 26 Years
Sex
All
01

Study summary

Severe mental illnesses (SMI), such as schizophrenia, are associated with increased morbidity and mortality in large part due to obesity and concomitant metabolic disorders. People with SMI have twice the risk of becoming obese, driven by the use of antipsychotic medications. These antipsychotic medications are dopamine antagonists, which reduce brain dopamine levels, leading to an increase in food reinforcement, which leads to weight gain. This weight gain occurs very rapidly with the initiation of these medications, as do increases in LDL cholesterol, insulin, and leptin.

While there have been attempts to develop weight loss programs, a recent meta-analysis concluded that these interventions led to statistically significant weight loss that was of no clinical significance and did not last beyond the intervention. Given the rapid weight gain/metabolic changes and the findings that it is easier to prevent weight gain than to lose weight, interventions targeting the early phases of a first episode of psychosis (FEP) are critical. However, the very few attempts have failed to address two key aspects of first episode psychosis. First, antipsychotic medications increase the reinforcing value of food and interventions have not included strategies to provide alternative reinforcements. Second, most patients experiencing FEP live with and are dependent on their parents, but existing interventions have not utilized parents in support of exercise and dietary changes.

The purpose of this project is to assess the feasibility and acceptability of, and to provide preliminary evidence for the efficacy of a Family-Based Treatment (FBT) that includes both the patient and the parent in the intervention and provides structured help in developing alternative reinforcements that support exercise and dietary changes. The specific aims of this project are:

  1. Recruit and provide FBT to 12 FEP patients and their parents using a multiple baseline single case experimental design;
  2. Evaluate participation, attrition, and satisfaction of the patients and their families across the three month treatment period;
  3. Examine the hypothesis that weight and food reinforcement will be significantly reduced during the treatment and follow-up phases in contrast to the baseline period.
Read the detailed description

C. Overview Study Sample: Twelve families will be recruited from NAVIGATE, a program for first episode psychosis patients. Patients in the program and who have been prescribed antipsychotic medications will be eligible. In addition, to be eligible, one of the parents must agree to work with the patient, and agree to modify their eating, exercise and if obese, their own weight. Patients and parents must be able to read at the 8th grade level. Patients or parents with a history or evidence of current eating disorders (bulimia or anorexia or binge eating disorder) or a current alcohol or drug use disorder will be excluded.

The NAVIGATE program admits 2 to 3 patients per month. At the beginning of the study, we anticipate that there would be approximately 40-45 patients in the program with the requisite use of antipsychotic medications, and over the next five months, we would expect an additional 10-15 patients. Assuming that 50% of the patients are eligible and interested, we would have approximately 25-30 patients available for the study.

Assessments: Participants will have a baseline session in which they complete the Behavioral Choice Questionnaire that assesses the reinforcing value of food. Parents and the patients will also complete questionnaires regarding parenting, time perspective, consideration of future consequences, and have their height and weight measured. Following the baseline assessment, baseline data will be collected over a two month period, and then families will be randomized to staggered initiation of treatment in blocks of 4 families. At the end of treatment, the patient and the participating parent will receive the same assessment battery that they completed for the baseline session. They will also provide information on the implementation of the diet, exercise, and alternative reinforcement procedures. After an additional 2 months, the patient and parent will return for the final assessment using the same assessment battery, as well as the implementation data.

During the baseline, treatment and follow-up period, patients will take their weight daily with a Bluetooth scale provided by the project.

Intervention: Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two "eating plan" education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity. Weekly sessions will involve discussion of weight loss principles presented in modules in the weight control manual, and coaching parents and patients how to implement the Traffic Light Eating Plan and healthy lifestyle techniques. At each session, participants meet with staff and attend a brief problem solving session with their case manager where they will troubleshoot any expected or encountered issues with implementing the program. As part of treatment, participants will weigh themselves daily with a Bluetooth scale.

An innovative aspect of this treatment is helping patients develop alternative reinforcements that do not involve food that can reduce the motivation to eat for the hedonic or reinforcing motivations. The first step is to identify alternative activities that have a higher reinforcement value than the patients' favorite foods. First, participants will identify potential alternatives from the 139 behaviors on the Pleasant Activities List. The therapist then works with the patient to better specify the behavior, ensure its feasibility and describe the parameters of the behavior (e.g. duration). After the participant and case manager agree on a list of alternatives (at least 5), the participant will complete the Behavioral Choice Questionnaire that assesses the reinforcing value of that activity in comparison to food. The most reinforcing food to be used to assess behavioral substitutes will be chosen from a list of usual meals that can be obtained from home cooked, fast food or casual dining restaurants. These alternative reinforcements are used non-contingently by the patients/parents to provide highly desirable activities that compete with excessive food consumption.

Design and analysis: The project is a multiple baseline single case experimental design, with a 2 month baseline data collection. Families will then be randomized to staggered initiation of treatment in blocks of 4 families. We anticipate having 8 participating families at the beginning of the project and would randomly assign them to start the baseline assessment between 1 and 9 weeks into the project, with the treatment then beginning between weeks 9 and 17. Treatment completion for this initial cohort would be between weeks 21 and 29, and the final follow-up would occur between weeks 29 and 37. Families entering NAVIGATE after the recruitment of the first cohort will be randomly assigned to start the baseline from 1 to 9 weeks after entry. This will provide a significant baseline (2 months) for all participants with different initial points for the study.

Analysis of the daily weights will involve discontinuous growth curve analysis using multi-level modeling. Separate models are developed for each participant which include the daily weights from the baseline (60 days), treatment (90 days) and follow-up (60 days) phases. Given the nature of the data, we would hypothesize significantly different slopes for the baseline vs treatment phases. We would also expect no significant differences between the slopes for the treatment phase and the follow-up phase. The primary analysis involves modeling each individual as a level one variable. This data may be examined at the individual level to provide information regarding the number of individuals responding to the treatment, as well as through meta-analysis to provide more specific effect sizes.

02

Conditions studied

  • Diet, Healthy
  • Psychotic Disorders

Browse trials for

03

In context

Psychotic Disorders

1,626 studies on the registry are indexed under Psychotic Disorders; 293 are open to participants now.

This study's enrollment of 10 is below the median of 70 across 1,333 interventional studies indexed under Psychotic Disorders.

Browse Psychotic Disorders studies →

Lead sponsor

State University of New York at Buffalo is the lead sponsor of 287 studies on the registry; 65 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Participant:

  • Age 14-26 years
  • Enrolled in NAVIGATE, a clinical program for patients with first episode of psychosis.
  • Prescribed antipsychotic medication for a first break psychotic episode
  • Availability of household family member to collaborate in the weight management program.

Family Member:

  • Lives in the same household as participant (e.g., parent, guardian, grandparent, aunt or uncle)
  • Able to attend weekly meetings with a case manager

Exclusion criteria

Exclusion Criteria:

Participant \& Family Member:

  • Personal or Family history or evidence of current eating disorders (bulimia or anorexia or binge eating disorder)
  • Current alcohol or drug abuse,
  • Unable to read at 8th grade level
  • Unable to use technology.
  • Unable to weigh themselves daily due to existing medical condition
  • Pregnant or planning on becoming pregnant during the study
05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Interventions

  • BehavioralFamily Based weight management program

    Weight management program that involve the patient AND a family member or a care taker. Families will receive a 12-week FBT adapted for first episode psychosis. This will be delivered in 12 weekly meetings with a trained case manager and two "eating plan" education sessions. Both the patient with psychosis and parents are targeted for eating and activity/exercise change to ensure a change in the shared family environment, which will also help weight control in both sets of participants, as well as medical issues that accompany obesity, including glycemic control, hypertension and hyperlipidemia. If parents are not overweight/obese, they will still target improved health behaviors. They will learn about GREEN, YELLOW, and RED foods (healthy vs. unhealthy foods), energy density, glycemic index of foods, reducing serving sizes, eating less, healthy lifestyle and programmed activity programs and recording their diets and activity.

06

What researchers measure

Primary outcomes

  1. Weight

    Change in weight will be assessed at baseline, weekly during study period, end point, and follow up.

    Time frame: 7 months

07

Results

Posted Jan 14, 2025

Participant flow

Dyads consisting of patients and their support person (one patient and one support person per dyad) were recruited from an outpatient clinic between 7/15/22 and 6/30/23

Participant flow — Overall Study
MilestonePatientsSupporting Person
Started55
Completed55
Not completed00

Outcome measures

PrimaryWeight

Change in weight will be assessed at baseline, weekly during study period, end point, and follow up.

Time frame:
7 months
Reported as:
Number · Lbs
Weight
LbsPatientsSupporting Person
Dyad 1-6-3
Dyad 2-5-4
Dyad 3115
Dyad 4-4-14
Dyad 50-7
Statistical analysis
  • Patients vs Supporting Person ·

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients0/5 (0%)0/5 (0%)0/5 (0%)
Supporting Person0/5 (0%)0/5 (0%)0/5 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PatientsSupporting PersonTotal
<=18 years101
Between 18 and 65 years459
>=65 years000
Age, Continuous
Age, Continuous(years)PatientsSupporting PersonTotal
Mean21.8 ± 3.138.2 ± 15.530 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)PatientsSupporting PersonTotal
Female145
Male415
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PatientsSupporting PersonTotal
Hispanic or Latino101
Not Hispanic or Latino459
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PatientsSupporting PersonTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American112
White235
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)PatientsSupporting PersonTotal
United States5510
Weight
Weight(Lbs)PatientsSupporting PersonTotal
Mean217.3 (190.9 to 239.2)201.5 (150.6 to 236.3)209.4 (150.6 to 239.2)
08

Study locations

1 site
  • Erie County Medical Center
    Buffalo, New York 14215, United States
09

References and documents

Publications

  • McElroy SL. Obesity in patients with severe mental illness: overview and management. J Clin Psychiatry. 2009;70 Suppl 3:12-21. doi: 10.4088/JCP.7075su1c.03. PubMed 19570497 ↗
  • Gates J, Killackey E, Phillips L, Alvarez-Jimenez M. Mental health starts with physical health: current status and future directions of non-pharmacological interventions to improve physical health in first-episode psychosis. Lancet Psychiatry. 2015 Aug;2(8):726-742. doi: 10.1016/S2215-0366(15)00213-8. PubMed 26249304 ↗
  • Daurignac E, Leonard KE, Dubovsky SL. Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men. Int Clin Psychopharmacol. 2015 Jan;30(1):23-8. doi: 10.1097/YIC.0000000000000052. PubMed 25350366 ↗
  • Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016 Jun;10(3):193-202. doi: 10.1111/eip.12251. Epub 2015 May 12. PubMed 25962699 ↗
  • Epstein LH, Bickel WK, Czajkowski SM, Paluch RA, Moeyaert M, Davidson KW. Single case designs for early phase behavioral translational research in health psychology. Health Psychol. 2021 Dec;40(12):858-874. doi: 10.1037/hea0001055. Epub 2021 Aug 9. PubMed 34370494 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 13, 2021
  • Informed consent form · Nov 15, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05207982
Lead sponsor
State University of New York at Buffalo
Collaborators
National Center for Advancing Translational Sciences (NCATS)
Responsible party
Daniel Antonius (Associate Professor, State University of New York at Buffalo) — Principal investigator
First posted
Jan 26, 2022
Start date
Jul 15, 2022
Primary completion
May 21, 2023
Completion
Jul 5, 2023
Results posted
Jan 14, 2025
Last update
Jan 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion